Significance of tumor microenvironment on the genesis of: Interstitial fluid, angiogenesis, haemostatic/haemorheologic abnormalities. Pathogenesis and therapeutic aspects

Cancer Microenvironment and Therapeutic Implications: Tumor Pathophysiology Mechanisms and Therapeutic Strategies

Volumn , Issue , 2009, Pages 39-61

  Baronzio, Gianfranco ^a   Freitas, Isabel ^b   Hau, Kwan ^c  

^a Policlinico di Monza   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Coagulation abnormalities; Hemorheology; Hemostasis; Hypoxia; Neoangiogenesis; Thrombosis; Trousseau syndrome; Tumor interstitial fluid; Tumor microenvironment

Indexed keywords

EID: 84900175673     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-9576-4_3     Document Type: Chapter

References (115)

1. Albini A., Tosetti F., Benelli R., and Noonan D.M.: Tumor inflammatory angiogenesis and its chemoprevention. Cancer Res. 2005 Dec 1; 65(23):10637-41
2. Andre P., Denis C.V., Ware J., et al.: Platelets adhere and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000; 96:3322-3328
3. Andrea N., and Ansell J.: Management of thrombosis in the cancer patient. Support Oncol. 2003; 1:235-245
4. Armulik A., Abramsson A., and Betsholtz C.: Endothelial/Pericyte Interactions. Circ res. 2005; 97:512-523
5. Aukland K., and Reed R.K.: Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev. 1993; 73:1-78
6. Baluk P., Hashizume H., and McDonald D.M.: Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005 Feb; 15(1):102-11
7. Baronzio G.F., and Freitas I.: Tumor environment genesis and implications on cancer immune response. In Atlas effector of Antitumor Immunity, Kiselevsky M.V. Editor., Springer Science + Business New York, Berlin 2008, pp. 25-43
8. Baronzio G.F., Freitas I., and Kwaan H.C.: Tumor microenvironment and hemorheological abnormalities. Semin Thromb Hemost. 2003;29:489-97
9. Blom J.W., Doggen C.J., Osanto S. et al.: Malignancies, prothrombotic mutations and the risk of venous thrombosis. JAMA. 2005; 293:715-722
10. Boccaccio C., and Comoglio P.M.: A functional role for hemostasis in early cancer development. Cancer Res. 2005; 65:8579-82
11. Born G.V.R., Gorog P., and Kratzer M.A.A.: Interaction of the Platelets and the Vessel Walls. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. Aug. 18, 1981; 294:241-250
12. Brock T.A., Dvorak H.F., and Senger D.R.: Tumor secreted vascular permeability factor increase cytosolic Ca2+ and von Willebrand Factor release in human endothelial cells. Am J Pathol. 1991; 138:213-221
13. Butler T.P., Grantham F.H., and Gullino P.M.: Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res. 1975; 35:3084-8
14. Caine G.J., Stonelake P.S., Lip G.Y. et al.: The hypercoagulable state of malignancy: Pathogenesis and current debate. Neoplasia 2002; 4:465-473
15. Chang J., Powles T.J., Gregory R.K. et al.: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulatuion factors in healthy popstmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol. 1996; 7: 671-675
16. Chung I., and Lip G.Y.H.: Virchow's triad revisited: Blood constituents. Pathophysiol Haemost Thromb 2003/2004; 33:449-454
17. Collen A., Smorenburg S.M., Peters E. et al.: Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res. 2000; 60:6196-6200
18. Colombo M.P., and Mantovani A.: Targeting myelomonocytic cells to revert inflammationdependent cancer promotion. Cancer Res. 2005 Oct 15; 65(20):9113-6
19. Colvin B.T.: Physiology of hemostasis. Vox Sang. 2004; 87 Suppl1:43-6
20. Crowther M., Brown N.J., Bishop E.T., and Lewis C.E.: Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J Leukoc Biol. 2001 Oct; 70(4):478-90
21. Czekay R.P., and Loskutoff D.J.: Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood). 2004; 229:1090-6
22. Denko N.C., and Giaccia A.J.: Tumor Hypoxia, the Physiological Link between Trousseau's Syndrome (Carcinoma-induced Coagulopathy) and Metastasis. Cancer Res. 2001; 61: 795-798
23. Desai A.A., Vogelzang N.J., Rini B.I. et al.: A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002; 95:1629-36
24. Duggan C., Marriott K., Edwards R. et al.: Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol. 2003 Oct 1; 21(19):3588-93
25. Dvorak H.F.: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002; 20:4368-80
26. Einav S., and Bluestein D.: Dynamics of blood flow and platelet transport in pathological vessels. Ann NY Acad Sci. 2004; 1015:351-366
27. Erman M., Abali H., Oran B., et al.: Tamoxifen-induced tissue factor pathway inhibitor reduction: A clue for an acquired thrombophilic state? Ann Oncol. 2004 Nov; 15(11):1622-6
28. Ferrara N., and Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18:4-25
29. Frede S., Berchner-Pfannschmidt U., and Fandrey J.: Regulation of hypoxia-inducible factors during inflammation. Methods Enzymol. 2007; 435:405-19
30. Freitas I., Baronzio G.F., Bono B. et al.: Tumor interstitial fluid: Misconsidered component of the internal milieu of a solid tumor. Anticancer Res. 1997; 17:165-72
31. Freytes C.O.: Thromboembolic complications related to central venous access catheters in cancer patients. Semin Thromb Hemost. 2007; 33:389-396
32. Fukumura D., and Jain R.K.: Tumor microvasculature and microenvironment: Targets for antiangiogenesis and normalization. Microvasc Res. 2007; 74:72-84
33. Gasic G.J.: Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984; 3:99-114
34. Goh P.P., Sze D.M., and Roufogalis B.D.Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets. 2007; 7:743-58
35. Gullino P.M., Grantham F.H., and Smith S.H.: The interstitial water space of tumors. Cancer Res. 1965.25:727-31
36. Gullino P.M.: The internal milieu of tumors. Prog Exp Tumor Res. 1966; 8:1-25
37. Gunsilius E., Petzer A., Stockhammer G. et al.: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000; 58:169-74
38. Guyton A.C., Hall J.E.: The microcirculation and the lymphatic system: Capillary fluid exchange, interstitial fluid, and lymph flow. In Textbook of Medical physiology. Guyton A.C, and Hall J.E. editors. Elsevier Saunders publishers, Philadelphia, USA. 2006; pp. 181-194
39. Handin R.I.: Bleeding and Thrombosis. In Harrison Principles of Internal Medecine. Kaspoer D.L, Braunwald E, Fauci A., Hauser S.L., Longo D.L, and Jameson J.L. editors. McGraw Hill Editor. New York, Chicago London. 2005; pp. 337-343
40. Heit J.A., O'Fallon W.M., Petterson T.M., et al.: Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med. 2002; 162:1245-1248
41. Heldin C.H., Rubin K., Pietras K. et al.: High interstitial fluid pressure - An obstacle in cancer therapy. Nat. Rev Cancer. 2004; 4:806-813
42. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al.: Heparin and low-molecular-weight heparin. Chest. 2001; 119:64s-94s
43. Hirsh J.: Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest. 2007; 131:275-277
44. Hoffman M., and Monroe D.M.: Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin North Am. 2007; 21:1-11
45. Horton J.: Venous thrombotic events in cancer: The bottom line. Cancer Control. 2005; 12: 31-37
46. Jain R.K.: Transport of molecules in the tumor interstitium: A review. Cancer Res. 1987; 47: 3039-51
47. Jain R.K.: Determinants of tumor blood flow: A review. Cancer Res. 1988; 48:2641-2658
48. Juhan-Vague I., Renucci J.F., GrimauxM. et al.: Thrombin-Activatable fibrinolysis inhibitor antigen levels in cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000; 20:2156-2161
49. Jurasz P., Alonso-Escolano D., and Radomski M.W.: Platelet - cancer interactions: Mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004 Dec; 143(7):819-26
50. Kakkar V.V., and De Lorenzo F.: Prevention of venous thromboembolism in general surgery. Baillieres Clin Hematol. 1998 Sep; 11(3):605-19
51. Karihtala P., and Soini Y.: Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS. 2007; 115:81-103
52. Kim J.W., and Dang C.V.: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006 Sep 15; 66(18):8927-30
53. Kwaan H.C.: The biologic role of components of the plasminogen-plasmin system. Prog Cardiovasc Dis. 1992a; 34:309-316
54. Kwaan H.C.: The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev. 1992b; 11:291-311
55. Kwaan H.C., Wang J., Svoboda K., and Declerck P.J.: Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer. 2000; 82:1702-1708
56. Kwaan H.C., and Vicuna B.: Thrombosis and bleeding in cancer patients. Oncol Rev. 2007; 1: 14-27
57. Lamagna C., Aurrand-Lions M., and Imhof B.A.: Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol. 2006; 80:705-713
58. Lee A.Y.Y., and Levine M.N.: The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25:137-145
59. Letai A., and Kuter D.J.: Cancer, coagulation, and anticoagulation. Oncologist. 1999; 4:443-9
60. Levick J.R.: An Introduction to Cardiovascular Physiology. 2nd ed. Butterworth/Heineman Publisher. Oxford, UK. 1995; pp. 158-187
61. Levine M.N., and Lee A.Y.Y.: Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost. 1999; 25:245-249
62. Lewis C., and Murdoch C.: Macrophage responses to hypoxia: Implications for tumor progression and anti-cancer therapies. Am J Pathol. 2005; 167:627-35
63. Liao H.: Molecular regulation of the PAI-1 gene by hypoxia: Contributions of Egr-1, HIF-1?, and C/EBP?. The FASEB J. 2007; 21:935-949
64. Loreto M.F., De Martinis M., Corsi M.P. et al.: Coagulation and cancer: Implications for diagnosis and management. Pathol Oncol Res. 2000; 6:301-312
65. Lowe G.D.O.: Virchow's triad revisited: Abnormal blood flow. Pathophysiol Haemost Thromb 2003/2004; 33:455-457
66. Lox C.D., Ronaghan C.A., Cobos E., et al.: Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer. Clin Appl Thromb Hemost 1997; 3: 234-238
67. Lwaleed B.A., Cooper A.J., Voegeli D. et al.: Tissue factor: A critical role in inflammation and cancer. Biol Res Nurs. 2007; 9:97-107
68. Maeda H., Wu J., Sawa T. et al.: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release. 2000; 65:271-84
69. Mannucci P.M., Bettega D., Chantarangkul V. et al.: Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996; 156:1806-10
70. McDonald D.M., and Baluk P.: Significance of blood vessel leakiness in cancer. Cancer Res. 2002; 62:5381-5385
71. McDonald D.M., and Foss A.J.: Endothelial cells of tumor vessels: Abnormal but not absent. Cancer Metastasis Rev. 2000; 19:109-120
72. Milosevic M., Fyles A., and Hill R.: Interstitial fluid pressure in cervical cancer: Guide to targeted therapy. Am J Clin Oncol. 2001; 24:516-21
73. Morel O., Morel N., Hugel B., Jesel L., Vinzio S., Goichot B., Bakouboula B., Grunebaum L., Freyssinet J.M., and Toti F.: Les microparticules circulantes: Roles physiologiques et implications dans les maladies inflammatoires et thrombiques. Le Revue De Medicine Interne. 2005; 26:791-801
74. Morel O., Morel N., Freyssinet J.M., and Toti F.: Platelet microparticles and vascular cells interactions: A checkpoint between the hemostatic and thrombotic responses. Platelets. 2008; 19:9-23
75. Morikawa S., Baluk P., Kaidoh T., et al.: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002; 160:985-1000
76. Murdoch C., Muthana M., and Lewis C.E.: Hypoxia regulates macrophage functions in inflammation. J Immunol. 2005 Nov 15; 175(10):6257-63
77. Myohanen H., and Vaheri A.: Regulation and interactions in the activation of cell-Associated plasminogen. Cell Mol Life Sci 2004; 61:2840-2858
78. Nagy J.A., Brown L.F., Senger D.R. et al.: Pathogenesis of tumor stroma generation: A critical role offor leaky blood vessels and fibrin deposition. Biochim Biophys Acta. 1989; 948:305-326
79. Nierodzik M.L., and Karpatkin S.: Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006 Nov; 10(5):355-62
80. Nijziel M.R., Van Oerle R., Hillen H.F.P. et al.: From trousseau to angiogenesis: The link between the hemostatic system and cancer. Neth J Med. 2006; 64:403-10
81. Noel A., Maillard C., Rocks N., Jost M., et al.: Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol. 2004 Jun; 57(6):577-84
82. Norris L.A.: Blood coagulation. Best Pract Res Clin Obstet Gynaecol. 2003; 17:369-83
83. Ramos Y., and Nyska A.: Drug-induced thrombosis-experimental, clinical, and mechanicistic considerations. Toxicol Pathol. 2007; 35:208-225
84. Rella C., Coviello M., Giotta F. et al.: A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996; 40:151-9
85. Richardson P.D., and Longmore D.B.: Rheological factors in platelet-vessel wall interactions. Philos Trans R Soc Lond B Biol Sci. 1981; 294:251-266
86. Riddel J.P., Bradley E.A., Miaskowski C. et al.: Theories of blood coagulation. J Pediatr Oncol Nurs. 2007; 24:123-31
87. Shepro D., and Morel N. M. Pericyte physiology. FASEB J. 1993; 7:1031-8
88. Sierko E., andWojtukiwiewiczM.Z.: Inhibition of platelet function: Does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007; 33:712-21
89. Sierko E., and Wojtukiwiewicz M.Z.: Platelets and angiogenesis in malignancy. Semin Thromb Hemost. 2004; 30:95-108
90. Simionescu N., and Simionescu M.: The cardiovascular system. In Cell and Tissue Biology. A Textbook of Histology. Leon Weiss Editor. Urban & Schwarzenberg Publisher. Baltimore-Munich. 1998; pp. 355-398
91. Simon J.M.: Hypoxia and angiogenesis. Bull Cancer. 2007; 94:S160-5
92. Smith R.E., Janjan N., Kretzschmar S., and Hackbarth D.: The effect of radiation therapy on von Willebrand factor in patients with angiosarcoma. Radiother Oncol. 1989; 16:297-304
93. Soff G.A., Sanderowitz J., Gately S., Verusio E. et al.: Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumorassociated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995; 96:2593-2600
94. Starling E.H. On the Absorption of Fluids from the Connective Tissue Spaces. J Physiol. 1896; 19:312-26
95. Stevenson J.L., Choi S.H, and Varki A.: Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, non antithrombotic activity. Clin Cancer Res. 2005; 11:7003-7011
96. Stohrer M., Boucher Y., Stangassinger M. et al.: Oncotic pressure in solid tumors is elevated. Cancer Res. 2000; 60:4251-5
97. Uchiyama S., Yamazaki M. and Maruyama S.: Role of platelet-Activating factor in aggregation of leukocytes and platelets in cerebral ischemia. Lipids. 1991; 26:1247-9
98. Van Heeckeren W.J., Sanborn S.L., Narayan A. et al.: Complications from vascular disrupting agents and angiogenesis inhibitors: Aberrant control of hemostasis and thrombosis. Curr Opin Hematol. 2007; 14:468-80
99. Van Hinsbergh V.W.M.: The endothelium: Vascular control of hemostasis. Eur J Obstet Gynecol Reprod Biol. 2001; 95:198-201
100. Van Kempen L.C.L.T, Ruiter D.J., Goos N.P. et al.: The tumor microenvironment: A critical determinant of neoplastic evolution. Eur J Cell Biol. 2003; 82:539-48
101. Varki A.: Trousseau's syndrome: Multiple definitions and multiple mechanisms. Blood. 2007; 110:1723-1729
102. Vaupel P., and Mayer A.: Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26:225-39
103. Vassalli J.D., Sappino A.P., and Belin D.: The plasminogen activator/plasmin system. J Clin Invest. 1991; 88:1067-1072
104. Verheul H.M., Jorna A.S., Hoekman K. et al.: Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood. 2000; 96:4216-21
105. Virchow R.: Neuer fall von todlichen. Emboli Der lungenarterie. Arch Pathol Anat. 1856; 10: 225-28
106. Vitseva O., Flockhart D.A., Jin Y. et al.: The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. JPET 2005; 312:1144-1150
107. von Tempelhoff G.F., Schönmann N., Heilmann L., et al.: Prognostic role of plasmaviscosity in breast cancer. Clin Hemorheol Microcirc. 2002; 26:55-61
108. Wang J., Weiss I., Svoboda K. et al.: Thrombogenic role of cells undergoing apoptosis. Br J Hematol. 2001; 115:382-91
109. Weitz J.I.: Low-molecular-weight heparins. New Engl J Med. 1997; 337:688-698
110. Widakowich C., De Castro G., Jr, De Azambuja E. et al.: Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist. 2007 Dec; 12(12):1443-55
111. Wojtukiewicz M.Z., Sierko E., Klement P., and Rak J.: The hemostatic system and angiogenesis in malignancy. Neoplasia. 2001; 3:371-84
112. Xian X., H'akansson J., St'ahlberg A., Lindblom P. et al.: Pericytes limit tumor cell metastasis. J Clin Invest. 2006; 116:642-51
113. Yu J.L., May L., Klement P. et al.: Oncogenes as regulators of tissue factor expression in cancer: Implications for tumor angiogenesis and anti-cancer therapy. Semin Thromb Hemost. 2004; 30:21-30
114. Zakarija A., and Kwaan H.C.: Adverse effects on haemostatic function caused by drugs used in hematologic malignancies. Sem Thromb Hemost. 2007; 33:355-364
115. Zacharski L.R., Prandoni P., and Monreal M.: Warfarin versus low - molecular - weight heparin therapy in cancer patients. Oncologist 2005; 10:72-79.